1. CD40 ligand is required for protective cell-mediated immunity to Leishmania major.
- Author
-
Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, and Maliszewski CR
- Subjects
- Animals, CD40 Ligand, Disease Susceptibility, Immunity, Cellular, Interleukin-12 biosynthesis, Interleukin-12 genetics, Interleukin-12 therapeutic use, Leishmaniasis, Cutaneous genetics, Ligands, Macrophages, Peritoneal metabolism, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Recombinant Proteins therapeutic use, Th1 Cells immunology, CD40 Antigens physiology, Leishmania major immunology, Leishmaniasis, Cutaneous immunology, Leishmaniasis, Cutaneous prevention & control, Membrane Glycoproteins physiology, Membrane Glycoproteins therapeutic use
- Abstract
The CD40-CD40 ligand (CD40L) signaling process is a pivotal component of multiple immunoregulatory pathways. Although the role that CD40L plays in humoral immune responses is fairly well defined, its function(s) in cell-mediated responses in vivo has not been established. We investigated this issue by assessing the course of Leishmania major infection in CD40L knockout (CD40LKO) mice that were generated on a resistant background. In response to parasite challenge, CD40LKO mice developed ulcerating cutaneous lesions and failed to mount a vigorous Th1-like response. The impaired Th1-like response appears to be related to a defect in the ability of CD40LKO T cells to induce the production of IL-12 from macrophages. Treatment with exogenous IL-12 prevented disease progression in CD40LKO mice, and administration of recombinant CD40L provided partial protection against infection. Thus, a protective cell-mediated immune response to L. major appears to be dependent upon CD40L-induced IL-12 secretion by antigen-presenting cells.
- Published
- 1996
- Full Text
- View/download PDF